A Controlled Trial of Early versus Late Treatment with Zidovudine in Symptomatic Human Immunodeficiency Virus Infection
Open Access
- 13 February 1992
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 326 (7), 437-443
- https://doi.org/10.1056/nejm199202133260703
Abstract
Zidovudine is recommended for asymptomatic and early symptomatic human immunodeficiency virus (HIV) infection. The best time to initiate zidovudine treatment remains uncertain, however, and whether early treatment improves survival has not been established.This publication has 11 references indexed in Scilit:
- Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infectionNeurology, 1991
- Zidovudine and the Natural History of the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1991
- A Randomized Controlled Trial of a Reduced Daily Dose of Zidovudine in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1990
- Population pharmacokinetics of zidovudineClinical Pharmacology & Therapeutics, 1990
- The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) InfectionAnnals of Internal Medicine, 1990
- Early Treatment for HIVNew England Journal of Medicine, 1990
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990
- The AIDS Dementia ComplexThe Journal of Infectious Diseases, 1988
- The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related ComplexNew England Journal of Medicine, 1987
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977